The transfer of newly-developed technology to medicine and other health products needs to be improved across the pharmaceutical industry, according to a new paper.
There is a growing disparity between innovations reaching the market in developed "middle income" economies and developing nations, findings by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) indicate.
Governments in low-income economies have been urged to improve links with pharmaceutical technology partners to facilitate better transfer to local markets.
Richer nations could help by providing advice and access to guidance from standard-setting bodies and developing technical processing competencies, according to the report.
IFPMA director general Eduardo Pisani said: "Through technology transfer, R&D-based pharmaceutical companies are helping partner companies around the world to make advanced medicines and vaccines for their local markets.
"This is stimulating economic and social development, while also contributing to the health of recipient countries' populations."
Last month, the IFPMA underlined the growing threat posed by counterfeit medicine production to the industry.
The organisation noted that there has been an increase in reports of problems caused by counterfeit medicines globally, highlighting the need for unilateral action on both a local and international scale.
Typical Guttridge equipment used in the pharmaceutical industry includes; Hoppers – mobile loading hoppers – flexible bulk containers
